Nicolas Sayegh, Genitourinary Oncology Research Fellow at Huntsman Cancer Institute, shared an article on X:
“Superstar Zeynep Irem Ozay presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients.”
More posts featuring Nicolas Sayegh and ASCO 2025 on OncoDaily.